0
Il n'y a pas de produit dans le panier !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Accueil > Kits > PD-L1 > EP-133

PD-L1 : PD-1 [Biotinylated] Inhibitor Screening ELISA Kit

For research use only.

Order Now

IDComponentsSize
EP133-C01High-bind Plate1 plate
EP133-C02Human PD-L110 μg
EP133-C03Biotinylated Human PD-130 μg
EP133-C04Anti-PD-L1 Neutralizing Antibody20 μg
EP133-C05Streptavidin-HRP10 μg
EP133-C06Coating Buffer12mL
EP133-C0710xWashing Buffer 50mL
EP133-C08Blocking Buffer50mL
EP133-C09Substrate Solution12mL
EP133-C10Stop Solution7mL
  • Background
    Immune checkpoint pathway is a focal point of today’s cancer research. PD-1 is one of the best characterized checkpoint proteins. The binding between PD-1 and its ligand PD-L1 suppresses T-cell activation and allows cancer cells to escape from body’s immune surveillance. Therefore, the pharmaceutical inhibition of PD-1 or its ligand has been considered a promising strategy by many oncologists.
  • Application

    This kit is developed for screening for inhibitors of human PD-L1 binding to human PD-1.

    It is for research use only.

  • Reconstitution
    Please see Certificate of Analysis for details of reconstitution instruction and specific concentration.
  • Storage
    Unopened kit should be stored at 2°C -8°C upon receiving. Find the expiration date on the outside packaging and do not use reagents past their expiration date.

    The opened kit should be stored per components table. The shelf life is 30 days from the date of opening.

  • Assay Principles
    This inhibitor screening ELISA kit is designed to facilitate the identification and characterization of new PD-L1 pathway inhibitors. The assay takes advantage of our in house-developed binding of biotinylated human PD-1 to immobilized human PD-L1 in a functional ELISA assay, and employs a simple colorimetric ELISA platform. Briefly, we provide you with a human Biotinylated PD-1 protein, a human PD-L1 protein, an anti-PD-L1 neutralizing antibody (as method verified Std.), and Streptavidin-HRP reagent.

    Your experiment will include 4 simple steps:

    a) Coat the plate with human PD-L1.

    b) Add your molecule of interest to the tests.

    c) Add human PD-1-Biotin to bind the coated human PD-L1.

    d) Add Streptavidin-HRP followed by TMB or other colorimetric HRP substrate.

    Finally, the half maximal inhibitory concentration (IC50) of your compound to PD-L1: PD-1 binding will be determined by comparing OD readings among different experimental groups.

Typical Data Please refer to Ds document for the assay protocol.
 PD-L1 TYPICAL DATA

INHIBITION OF PD-L1: PD-1[Biotinylated] BINDING BY ANTI-PD-L1 NEUTRALIZING ANTIBODY
Serial dilutions of Anti-PD-L1 Neutralizing antibody (Catalog # EP133-C04) (1:1 serial dilution, from 2 μg/mL to 0.015625μg/mL) was added into PD-L1: Biotinylated PD-1 binding reactions. The assay was performed according to the protocol described below. Background was subtracted from data points prior to log transformation and curve fitting (QC tested).

  • Clinical and Translational Updates

Comments (0)


ETA des produits en stock: 2 jours ouvrables

Price(EUR) : €660.00

Promotion & Exhibitions



Drug Development Status

  • Number of Launched Drugs:7 Details
  • Number of Drugs in Clinical Trials:156 Details
  • Latest Research Phase:Phase 2 Clinical

Datasheet & Documentation

Request for DMF
DMF (Drug Master File)

New Product Launch

Questions & Comments

This web search service is supported by Google Inc.

totop

Laisser un message